LSN’s Fundraising Workshop Series in Taipei on July 25-26

By Jessica Yang, Investor Research Analyst, LSN

Life Science Nation (LSN) is going to exhibit and organize a series of Fundraising Workshops during the BIO ASIA Taiwan International Conference and Exhibition on July 25-28 in Taipei Nangang Exhibition Center, Hall 1, 4F. Come join us for two complimentary workshops on July 25 and July 26.

Workshop Venue: Taipei Nangang Exhibition Center, Hall 1, 4F, Number N930, Room 1

July 25, 2-3 PM (GMT+8)

Fundraising Boot Camp

A fundraising workshop that explains the nuances of creating and managing an effective outbound fundraising campaign. The content is tailored towards emerging and experienced scientist-entrepreneurs seeking to raise capital.

  • About Life Science Nation (LSN)
  • Raising Capital: The 3 Most Important Questions
  • The Changing Investor Landscape
  • Debunking the Top 10 Old Myths in Fundraising
  • Planning & Infrastructure for an Outbound Fundraising Campaign
  • Building Your Brand Through Consistent Messaging
  • Key Components of Fundraising Marketing Collateral

July 26, 10-11 AM (GMT+8)

Branding & Messaging Workshop

To win capital, you must stand out from the crowd. The first way to do that is to have top-notch marketing collateral. The workshop discusses how to provide potential investors with high-quality, professional materials—materials that engage them, communicate your message clearly and concisely, and present the information they want to see in a way that helps them to decide quickly and easily if you are a potential fit for their needs.

We also welcome everyone to visit our booth at number M628! Simply leave your business card when you visit our booth, and you will get a chance to win a free ticket to the RESI Asia Taipei Conference on November 14 2019.

Speakers:

Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career finding, vetting and launching a myriad of technology-based companies. Over the last decade, he has worked extensively with global alternative investors and is deeply interested in getting funding for high-growth early-stage technologies. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. In today’s context Dennis can connect early stage life science companies with 10 categories of global partners thus making the finding of capital and distribution channels very efficient. Dennis created the Redefining Early Stage Investments conference series to facilitate an interactive ongoing dialog between buyers and sellers in the life science arena. Before LSN, Dennis was the President and CEO of a company that improved the way hedge fund and private equity fund managers raised capital and marketed their funds to investors.

Ford is the author of The Peddler’s Prerogative and The Life Science Executive’s Fundraising Manifesto, two well-received sales and marketing books.

Greg Mannix, VP of International Business Development, Life Science Nation

../../../greg.pngGreg Mannix is VP of International BD at LSN. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French.

Greg relocated to Boston 3 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

Jessica Yang – Senior Investor Research Analyst, Life Science Nation

At LSN, Jessica Yang is responsible for curating the LSN Investor Platform and manages relationships with an extensive network of investors and Asia strategic partners across the globe. Jessica also leads LSN’s business development efforts in Taiwan and recently led collaboration efforts with the local government organization in bringing a large delegation of Taiwanese start-ups to RESI. Jessica also organized a series of fundraising workshops in Taiwan to help over 100 fundraising companies. Prior to joining LSN, Jessica has worked in GENEWIZ in New Jersey and Roche Diagnostics in Taiwan with product marketing projects, where she became passionate about becoming more involved in the life sciences industry. Jessica received a Master of Science Degree from New York University in Biotechnology and Entrepreneurship and a Bachelor of Science Degree from Chang Gung University in Medical Biotechnology.

Hot Investor Mandate: Seed Fund Invests in Life Science Platforms, Focusing on Computational Bio, DNA and Cellular Engineering

A seed-stage venture fund focusing on the frontiers of the intersection of science and technology is looking for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. For all investments, the firm prefers that there is a deep data science or computational element to the technology being commercialized. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. Ideally, these technologies are also leveraging computation to accomplish their ends. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Corporate VC Invests in Orthopedics and Nutritional Health

The corporate venture capital arm of a global science-based company active in health, nutrition and materials makes equity investments into seed and venture stage companies generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking to make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

Where it comes to Biomedical, the firm is looking for materials science companies in orthopedics and soft tissue repair. The firm also actively invests in human nutritional health, with a specific focus on companies active in personalized nutrition, and companies developing nutritional products. While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.

The firm highly values experience in a firms management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with their core businesses.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China Investment Management Firm Invests in Early Stage Medtech Deals

An investment management firm based in Tianjin, China manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries including healthcare. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Strategics and Angels Join Together to Allocate Up to $4 Million to Early Stage Companies

A Boston-based private investment group consisting of 145 early stage investors (strategics and angels) is currently looking for new opportunities in the life science space in seed to A rounds ranging from $100,000 to $4M. The group is open to reviewing opportunities from any country around the globe.

The group is open to all types of healthcare and life science companies including medical devices, therapeutics, diagnostics, healthcare equipment and laboratory instrumentation, digital health and material science. The firm looks for companies that have some proof-of-concept or validation data and at least a basic prototype prior to investment and is open to all classes of molecules and devices.

The group is looking for privately held companies with experienced management teams, the firm does not require a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Stand out at RESI Boston with the Innovation Challenge and Innovators’ Pitch Challenge

By Karen Deyo, Investor Research Analyst, LSN

At every RESI event, the RESI Innovation Challenge helps promising startups gain exposure with investors – many past finalists have spoken of how they used the Innovation Challenge as an opportunity to speak to more investors and form more relationships, using their participation as a catalyst. Companies participating in the Innovation Challenge are selected based on their innovativeness and their commercial potential, among other criteria, and finalists are provided with a poster presentation spot at RESI, in addition to being featured in the LSN newsletter and in the program guide. The portal to apply for Innovation Challenge for RESI Boston is now open, so we invite any companies interested in participating to apply now! The participating companies will compete to receive ‘investments’ of ‘RESI cash’ provided to all attendees, and the top three participants will receive prizes.

In addition to the RESI Innovation Challenge, participating tech hubs from the First Coast can have their constituents apply to participate in the First Coast Innovators’ Pitch Challenge. The top 8 companies from participating tech hubs will be selected to pitch to a panel of investors, giving them a chance to hone their pitch and receive valuable feedback.

The deadline for both the Innovation and Pitch Challenges for RESI Boston is August 7th – we look forward to receiving your application!

Jumping Out of an Airplane Without A Parachute

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

I used to teach an entrepreneurial sales class at a local university in Boston. The first day of my class I would pose a question right out of the box: ‘OK class, show of hands please! How many of you would jump out of an airplane without a parachute? Simple question, show of hands please.’ Inevitably in every class I would have one or two who for one reason or another may be considered on the margins (as entrepreneurs can be) would raise their hands. I would point out that there are one, maybe two, hands, the rest are just sitting there looking confused and anxious. At that point I would say ‘OK! Thank you class, the two that raised their hands can stay and the rest of you can go.’ This would lead to more confusion and fidgeting and finally, I would say, ‘let me give it to you all straight – you have joined this class because you have an idea or a company that you want to start. Taking an idea and starting you first company is the equivalent of jumping out of an airplane without a parachute.’

Yes, you may figure out something on the way down. Yes, you could somehow miraculously survive the fall. But, realistically the odds are, you are probably going to hit the ground and die. That is the world of the startup. It’s a learning process. It’s getting experience in something totally new and different. It’s learning from your mistakes. And then I would say ‘You are all welcome to stay, and now we have to figure out how not to kill your company.’

That is precisely the chances of you getting your first startup off the ground. The odds are stacked against you from the get-go. There is so much to learn and know. The good news is, if you have tried a few times and learned lots along the way, the better chance you have of figuring it out and surviving your next company. The message here is of course you will strike out the first few times you get up to bat, but if you persist, you adjust and eventually you make it, you get there. I’ve done about a dozen startups over the years: the first one died and the last one is heading into its seventh year.